Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 12
Profile of eliglustat tartrate in the management of Gaucher disease [Corrigendum]
Sechi A, Dardis A, Bembi B. Ther Clin Risk Manag. 2016; 12:53–58.
On page 57, left column, line 22, the text “patients who result in poor metabolizers should not be treated with this drug” should have been “patients who result in CYP2D6 ultra-rapid metabolizers or who are indeterminate metabolizers should not be treated with this drug”.
Read the original article
© 2016 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.